H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating on Akebia Therapeutics today and set a price target of $6.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Matthew Caufield has given his Buy rating due to a combination of factors that highlight Akebia Therapeutics’ strategic growth and potential in the kidney disease market. The company has announced an expansion of its kidney disease pipeline, which includes the acquisition of AKB-097, a tissue-targeted complement inhibitor, and the initiation of a Phase 2 trial for Praliciguat, aimed at treating focal segmental glomerulosclerosis (FSGS). These developments are seen as significant opportunities for diversification and growth beyond the existing commercial focus on VAFSEO and AURYXIA for chronic kidney disease (CKD) patients on dialysis.
Furthermore, the integration of VAFSEO into major dialysis organizations like US Renal Care, DaVita, and IRC clinics is progressing, with expectations of increased patient access and prescription rates. This expansion is anticipated to enhance Akebia’s market presence and drive growth into 2026 and beyond. The company’s financial position is also bolstered by a cash runway of at least two years, supported by recent acquisitions and milestone payments. These factors collectively reinforce the Buy rating with a price target of $6.00, reflecting confidence in Akebia’s strategic direction and market potential.